Mantle cell lymphoma – does primary intensive immunochemotherapy improve overall survival for younger patients?
Author:
Publisher
Informa UK Limited
Subject
Cancer Research,Oncology,Hematology
Link
http://www.tandfonline.com/doi/pdf/10.1080/10428190903040030
Reference50 articles.
1. Mantle cell lymphoma-- an entity comes of age
2. Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
3. Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
4. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network
5. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mantle Cell Lymphoma;Cancer Consult: Expertise for Clinical Practice;2014-06-20
2. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma;Haematologica;2012-02-07
3. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study;The Lancet Oncology;2011-04
4. Intensive therapies for mantle cell lymphoma: time for a disease-specific approach?;Leukemia & Lymphoma;2010-02-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3